{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:49:41Z","timestamp":1790264981382,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s10096-017-3114-5","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T07:55:52Z","timestamp":1507622152000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections"],"prefix":"10.1007","volume":"37","author":[{"given":"S. M. S.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S. P.","family":"Sioson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. M.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. S. V.","family":"Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W. P.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jureen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-3983","authenticated-orcid":false,"given":"C. S. B.","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"3114_CR1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","volume":"53","author":"N Gupta","year":"2011","unstructured":"Gupta N, Limbago BM, Patel JB, Kallen AJ (2011) Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 53:60\u201367","journal-title":"Clin Infect Dis"},{"key":"3114_CR2","doi-asserted-by":"crossref","first-page":"e02349","DOI":"10.1128\/AAC.02349-16","volume":"61","author":"MJ Satlin","year":"2017","unstructured":"Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G et al (2017) Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 61:e02349\u2013e02316","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.medmal.2013.11.007","volume":"44","author":"P Nordmann","year":"2014","unstructured":"Nordmann P (2014) Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 44:51\u201356","journal-title":"Med Mal Infect"},{"key":"3114_CR4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","volume":"68","author":"CM Baldwin","year":"2008","unstructured":"Baldwin CM, Lyseng-Williamson KA, Keam SJ (2008) Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 68:803\u2013838","journal-title":"Drugs"},{"key":"3114_CR5","doi-asserted-by":"crossref","first-page":"ofv050","DOI":"10.1093\/ofid\/ofv050","volume":"2","author":"HJ Morrill","year":"2015","unstructured":"Morrill HJ, Pogue JM, Kaye KS, LaPlante KL (2015) Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis 2:ofv050","journal-title":"Open Forum Infect Dis"},{"key":"3114_CR6","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.ijantimicag.2008.06.003","volume":"32","author":"PI Vergidis","year":"2008","unstructured":"Vergidis PI, Falagas ME (2008) New antibiotic agents for bloodstream infections. Int J Antimicrob Agents 32:S60\u2013S65","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2017.03.022","volume":"131","author":"MI El-Gamal","year":"2017","unstructured":"El-Gamal MI, Brahim I, Hisham N, Aladdin R, Mohammed H et al (2017) Recent updates of carbapenem antibiotics. Eur J Med Chem 131:185\u2013195","journal-title":"Eur J Med Chem"},{"key":"3114_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00042-16","volume":"30","author":"LY Hsu","year":"2017","unstructured":"Hsu LY, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A et al (2017) Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev 30:1\u201322","journal-title":"Clin Microbiol Rev"},{"key":"3114_CR9","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/jac\/dku084","volume":"69","author":"A Jain","year":"2014","unstructured":"Jain A, Hopkins KL, Turton J, Doumith M, Hill R et al (2014) NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. J Antimicrob Chemother 69:1777\u20131784","journal-title":"J Antimicrob Chemother"},{"key":"3114_CR10","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.02379-15","volume":"60","author":"KM Kazmierczak","year":"2015","unstructured":"Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ et al (2015) Multiyear, multinational survey of the incidence and global distribution of metallo-\u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:1067\u20131078","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13756-015-0066-3","volume":"4","author":"ML Ling","year":"2015","unstructured":"Ling ML, Tee YM, Tan SG, Amin IM, How KB et al (2015) Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control 4:26","journal-title":"Antimicrob Resist Infect Control"},{"key":"3114_CR12","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1128\/AAC.01359-16","volume":"60","author":"LF Mataseje","year":"2010","unstructured":"Mataseje LF, Abdesselam K, Vachon J, Mitchel R, Bryce E et al (2010) Results from the Canadian Nosocomial Infection Surveillance Program on carbapenemase-producing Enterobacteriaceae, 2010 to 2014. Antimicrob Agents Chemother 60:6787\u20136794","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR13","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1128\/AAC.01019-15","volume":"59","author":"JD Pitout","year":"2015","unstructured":"Pitout JD, Nordmann P, Poirel L (2015) Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59:5873\u20135884","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR14","first-page":"376","volume":"7","author":"Y Xu","year":"2015","unstructured":"Xu Y, Gu B, Huang M, Liu H, Xu T et al (2015) Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia. J Thorac Dis 7:376\u2013385","journal-title":"J Thorac Dis"},{"key":"3114_CR15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2015.09.015","volume":"22","author":"A Xu","year":"2016","unstructured":"Xu A, Zheng B, Xu YC, Huang ZG, Zhong NS et al (2016) National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin Microbiol Infect 22:S1\u2013S8","journal-title":"Clin Microbiol Infect"},{"key":"3114_CR16","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","volume":"17","author":"P Nordmann","year":"2011","unstructured":"Nordmann P, Naas T, Poirel L (2011) Global Spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791\u20131798","journal-title":"Emerg Infect Dis"},{"key":"3114_CR17","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","volume":"15","author":"LK Logan","year":"2017","unstructured":"Logan LK, Weinstein RA (2017) The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 15:S28\u2013S36","journal-title":"J Infect Dis"},{"key":"3114_CR18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/nyas.12537","volume":"1323","author":"E Temkin","year":"2014","unstructured":"Temkin E, Adler A, Lerner A, Carmeli Y (2014) Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann NY Acad Sci 1323:22\u201342","journal-title":"Ann NY Acad Sci"},{"key":"3114_CR19","unstructured":"Frieden T (2013) Antibiotic Resistance Threats in the United States, 2013. Executive Summary. Centers for Disease Control and Prevention, Atlanta, GA, USA. Available online: http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/ . Accessed 1 July 2017"},{"key":"3114_CR20","unstructured":"WHO (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. http:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/ . Accessed 1 July 2017"},{"key":"3114_CR21","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"ME Falagas","year":"2005","unstructured":"Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333\u20131341","journal-title":"Clin Infect Dis"},{"key":"3114_CR22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","volume":"58","author":"ME Falagas","year":"2014","unstructured":"Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS (2014) Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654\u2013663","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/14656566.2014.914172","volume":"15","author":"I Karaiskos","year":"2014","unstructured":"Karaiskos I, Giamarellou H (2014) Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15:1351\u20131370","journal-title":"Expert Opin Pharmacother"},{"key":"3114_CR24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijantimicag.2016.11.021","volume":"49","author":"H Zayyad","year":"2017","unstructured":"Zayyad H, Eliakim-Raz N, Leibovici L, Paul M (2017) Revival of old antibiotics: needs, the state of evidence and expectations. Int J Antimicrob Agents 49:536\u2013541","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR25","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/jac\/dku189","volume":"69","author":"K Brust","year":"2014","unstructured":"Brust K, Evans A, Plemmons R (2014) Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review. J Antimicrob Chemother 69:2606\u20131260","journal-title":"J Antimicrob Chemother"},{"key":"3114_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofv130.01","volume":"2","author":"HJ Morrill","year":"2015","unstructured":"Morrill HJ, Pogue JM, Kaye KS, LaPlante KL (2015) Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis 2:1\u201315","journal-title":"Open Forum Infect Dis"},{"key":"3114_CR27","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1086\/431672","volume":"41","author":"GA Noskin","year":"2005","unstructured":"Noskin GA (2005) Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 41:S303\u2013S314","journal-title":"Clin Infect Dis"},{"key":"3114_CR28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2015.06.011","volume":"83","author":"HS Sader","year":"2015","unstructured":"Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ et al (2015) Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). Diagn Microbiol Infect Dis 83:183\u2013186","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3114_CR29","doi-asserted-by":"crossref","first-page":"e0175140","DOI":"10.1371\/journal.pone.0175140","volume":"12","author":"SK Chiu","year":"2017","unstructured":"Chiu SK, Chan MC, Huang LY, Lin YT, Lin JC et al (2017) Tigecycline resistance among carbapenem-resistant Klebsiella pneumoniae: clinical characteristics and expression levels of efflux pump genes. PLoS One 12:e0175140","journal-title":"PLoS One"},{"key":"3114_CR30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1469-0691.2011.03482.x","volume":"18","author":"C Rodr\u00edguez-Avial","year":"2012","unstructured":"Rodr\u00edguez-Avial C, Rodr\u00edguez-Avial I, Merino P, Picazo JJ (2012) Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient. Clin Microbiol Infect 18:61\u201366","journal-title":"Clin Microbiol Infect"},{"key":"3114_CR31","unstructured":"FDA (2013) FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning. FDA, Rockville, MD. https:\/\/www.fda.gov\/drugs\/drugsafety\/ucm369580.htm . Accessed 1 July 2017"},{"key":"3114_CR32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/14787210.2014.894882","volume":"12","author":"D Dixit","year":"2014","unstructured":"Dixit D, Madduri RP, Sharma R (2014) The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti-Infect Ther 12:397\u2013400","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"3114_CR33","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/cis270","volume":"54","author":"P Prasad","year":"2012","unstructured":"Prasad P, Sun J, Danner RL, Natanson C (2012) Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54:1699\u20131709","journal-title":"Clin Infect Dis"},{"key":"3114_CR34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14787210.6.5.593","volume":"6","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Grammatikos AP, Michalopoulos A (2008) Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti-Infect Ther 6:593\u2013600","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"3114_CR35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2004.10.001","volume":"25","author":"J Li","year":"2005","unstructured":"Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25:11\u201325","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","volume":"6","author":"J Li","year":"2006","unstructured":"Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K et al (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589\u2013601","journal-title":"Lancet Infect Dis"},{"key":"3114_CR37","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijantimicag.2016.11.020","volume":"49","author":"KS Kaye","year":"2017","unstructured":"Kaye KS, Gales AC, Dubourg G (2017) Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes. Int J Antimicrob Agents 49:542\u2013548","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijantimicag.2016.11.001","volume":"48","author":"JM Pogue","year":"2016","unstructured":"Pogue JM, Ortwine JK, Kaye KS (2016) Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins? Int J Antimicrob Agents 48:622\u2013626","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","volume":"48","author":"TB Tran","year":"2016","unstructured":"Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT et al (2016) Pharmacokinetics\/ pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents 48:592\u2013597","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jac\/dku441","volume":"70","author":"B Yun","year":"2015","unstructured":"Yun B, Azad MA, Wang J, Nation RL, Thompson PE et al (2015) Imaging the distribution of polymyxins in the kidney. J Antimicrob Chemother 70:827\u2013829","journal-title":"J Antimicrob Chemother"},{"key":"3114_CR41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.1999.tb08636.x","volume":"884","author":"JM Aran","year":"1999","unstructured":"Aran JM, Erre JP, Lima da Costa D, Debbarh I et al (1999) Acute and chronic effects of aminoglycosides on cochlear hair cells. Ann NY Acad Sci 884:60\u201368","journal-title":"Ann NY Acad Sci"},{"key":"3114_CR42","first-page":"937861","volume":"2011","author":"ME Huth","year":"2011","unstructured":"Huth ME, Ricci AJ, Cheg AG (2011) Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolarynol 2011:937861","journal-title":"Int J Otolarynol"},{"key":"3114_CR43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/597031","volume":"48","author":"SE Cosgrove","year":"2009","unstructured":"Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR et al (2009) Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 48:713\u2013721","journal-title":"Clin Infect Dis"},{"key":"3114_CR44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/138161207779313731","volume":"13","author":"E Selimoglu","year":"2007","unstructured":"Selimoglu E (2007) Aminoglycoside-induced ototoxicity. Curr Pharm Des 13:119\u2013126","journal-title":"Curr Pharm Des"},{"key":"3114_CR45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.idc.2016.02.005","volume":"30","author":"KS Kaye","year":"2016","unstructured":"Kaye KS, Pogue JM, Tran TB, Nation RL, Li J (2016) Agents of last resort: polymyxin resistance. Infect Dis Clin N Am 30:391\u2013414","journal-title":"Infect Dis Clin N Am"},{"key":"3114_CR46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1473-3099(15)00533-2","volume":"16","author":"Y Hu","year":"2016","unstructured":"Hu Y, Liu F, Lin IY, Gao GF, Zhu B (2016) Dissemination of the mcr-1 colistin resistance gene. Lancet Infect Dis 16:146\u2013147","journal-title":"Lancet Infect Dis"},{"key":"3114_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2015.11.009","volume":"47","author":"AO Olaitan","year":"2016","unstructured":"Olaitan AO, Morand S, Rolain JM (2016) Emergence of colistin-resistant bacteria in humans without colistin usage: a new worry and cause for vigilance. Int J Antimicrob Agents 47:1\u20133","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR48","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijantimicag.2016.11.003","volume":"48","author":"AO Olaitan","year":"2016","unstructured":"Olaitan AO (2016) Emergence of polymyxin resistance in Gram-negative bacteria. Int J Antimicrob Agents 48:581\u2013582","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1039\/C5MD00344J","volume":"7","author":"S Garneau-Tsodikova","year":"2016","unstructured":"Garneau-Tsodikova S, Labby KJ (2016) Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. Med Chem Commun 7:11\u201327","journal-title":"Med Chem Commun"},{"key":"3114_CR50","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.00064-16","volume":"30","author":"L Poirel","year":"2017","unstructured":"Poirel L, Jayol A, Nordmann P (2017) Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 30:557\u2013596","journal-title":"Clin Microbiol Rev"},{"key":"3114_CR51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijantimicag.2015.11.010","volume":"47","author":"JM Rolain","year":"2016","unstructured":"Rolain JM, Olaitan AO (2016) Plasmid-mediated colistin resistance: the final blow to colistin? Int J Antimicrob Agents 47:4\u20135","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR52","doi-asserted-by":"crossref","unstructured":"Jayol A, Poirel L, Dortet L, Nordmann P (2016) National survey of colistin resistance among carbapenemase-producing Enterobacteriaceae and outbreak caused by colistin-resistant OXA-48-producing Klebsiella pneumoniae, France, 2014. Euro Surveill 21","DOI":"10.2807\/1560-7917.ES.2016.21.37.30339"},{"key":"3114_CR53","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ijantimicag.2016.11.029","volume":"49","author":"K Jeannot","year":"2017","unstructured":"Jeannot K, Bolard A, Pl\u00e9siat P (2017) Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents 49:526\u2013535","journal-title":"Int J Antimicrob Agents"},{"key":"3114_CR54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(16)30528-X","volume":"17","author":"J Quan","year":"2017","unstructured":"Quan J, Li X, Chen Y, Jiang Y, Zhou Z et al (2017) Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study. Lancet Infect Dis 17:400\u2013410","journal-title":"Lancet Infect Dis"},{"key":"3114_CR55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S1473-3099(16)30527-8","volume":"17","author":"Y Wang","year":"2017","unstructured":"Wang Y, Tian GB, Zhang R, Shen Y, Tyrrell JM et al (2017) Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study. Lancet Infect Dis 17:390\u2013399","journal-title":"Lancet Infect Dis"},{"key":"3114_CR56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2015.199","volume":"12","author":"HM Zowawi","year":"2015","unstructured":"Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, Schembri MA et al (2015) The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol 12:570\u2013584","journal-title":"Nat Rev Urol"},{"key":"3114_CR57","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.drudis.2014.07.005","volume":"19","author":"MS Kinch","year":"2014","unstructured":"Kinch MS, Patridge E, Plummer M, Hoyer D (2014) An analysis of FDA-approved drugs for infectious disease: Antibacterial agents. Drug Discov Today 19:1283\u20131287","journal-title":"Drug Discov Today"},{"key":"3114_CR58","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/nbt1206-1515","volume":"24","author":"R Brenner","year":"2006","unstructured":"Brenner R, Ellis-Grosse EJ, Echols R (2006) Moving goalposts - regulatory oversight of antibacterial drugs. Nat Biotechnol 24:1515\u20131520","journal-title":"Nat Biotechnol"},{"key":"3114_CR59","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/nbt1206-1497","volume":"24","author":"P Fernandes","year":"2006","unstructured":"Fernandes P (2006) Antibacterial discovery and development - The failure of success? Nat Biotechnol 24:1497\u20131503","journal-title":"Nat Biotechnol"},{"key":"3114_CR60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/clpt.2014.116","volume":"96","author":"S Nambiar","year":"2014","unstructured":"Nambiar S, Laessig K, Toerner J, Farley J, Cox E (2014) Antibacterial drug development: Challenges, recent developments, and future considerations. Clin Pharmacol Ther 96:147\u2013149","journal-title":"Clin Pharmacol Ther"},{"key":"3114_CR61","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB (2004) Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673\u2013683","journal-title":"Nat Rev Drug Discov"},{"key":"3114_CR62","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo N (2016) New tricks for old drugs. Nature 534:314\u2013316","journal-title":"Nature"},{"key":"3114_CR63","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","volume":"14","author":"TI Oprea","year":"2012","unstructured":"Oprea TI, Mestres J (2012) Drug repurposing: Far beyond new targets for old drugs. AAPS J 14:759\u2013763","journal-title":"AAPS J"},{"key":"3114_CR64","unstructured":"Clinical and Laboratory Standards Institute (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard, 9th ed, vol 32, no. 2. Document M07-A9. CLSI, Wayne, PA, USA"},{"key":"3114_CR65","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jac\/dkl393","volume":"58","author":"GL French","year":"2006","unstructured":"French GL (2006) Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J Antimicrob Chemother 58:1107\u20131117","journal-title":"J Antimicrob Chemother"},{"key":"3114_CR66","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0732-8893(93)90087-N","volume":"16","author":"MH Hsieh","year":"1993","unstructured":"Hsieh MH, Yu CM, Yu VL, Chow JW (1993) Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis 16:343\u2013349","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3114_CR67","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1128\/AAC.02684-13","volume":"58","author":"HS Sader","year":"2014","unstructured":"Sader HS, Farrell DJ, Flamm RK, Jones RN (2014) Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother 58:2274\u20132280","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR68","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1128\/AAC.34.6.1227","volume":"34","author":"PM Small","year":"1990","unstructured":"Small PM, Chambers HF (1990) Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34:1227\u20131231","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR69","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","volume":"10","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R (2005) FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10:176\u2013182","journal-title":"Oncologist"},{"key":"3114_CR70","first-page":"202","volume":"84","author":"PA Jones","year":"1983","unstructured":"Jones PA, Taylor SM, Wilson VL (1983) Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 84:202\u2013211","journal-title":"Recent Results Cancer Res"},{"key":"3114_CR71","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood.V90.4.1403","volume":"90","author":"T Uchida","year":"1997","unstructured":"Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H et al (1997) Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90:1403\u20131409","journal-title":"Blood"},{"key":"3114_CR72","first-page":"219","volume":"50","author":"EJ Freireich","year":"1966","unstructured":"Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219\u2013244","journal-title":"Cancer Chemother Rep"},{"key":"3114_CR73","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/0006-2952(73)90137-8","volume":"22","author":"BA Chabner","year":"1973","unstructured":"Chabner BA, Drake JC, Johns DG (1973) Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochem Pharmacol 22:2763\u20132765","journal-title":"Biochem Pharmacol"},{"key":"3114_CR74","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2110-5820-1-30","volume":"1","author":"AS Michalopoulos","year":"2011","unstructured":"Michalopoulos AS, Falagas ME (2011) Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 1:30\u201335","journal-title":"Ann Intensive Care"},{"key":"3114_CR75","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","volume":"49","author":"G Muralidharan","year":"2005","unstructured":"Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S (2005) Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49:220\u2013229","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR76","unstructured":"EMA (2017) EMA public assessment report on Vidaza. Document number: Vidaza -EMEA\/H\/C\/000978 -IB\/0040. Date: 20\/03\/2017. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000978\/WC500050239.pdf . Accessed 4 October 2017"},{"key":"3114_CR77","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/1535-7163.MCT-08-0709","volume":"8","author":"DG Power","year":"2009","unstructured":"Power DG, Kemeny NE (2009) The role of floxuridine in metastatic liver disease. Mol Cancer Ther 8:1015\u20131025","journal-title":"Mol Cancer Ther"},{"key":"3114_CR78","doi-asserted-by":"crossref","first-page":"e2001644","DOI":"10.1371\/journal.pbio.2001644","volume":"15","author":"MA Wambaugh","year":"2017","unstructured":"Wambaugh MA, Shakya VPS, Lewis AJ, Mulvey MA, Brown JCS (2017) High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance. PLoS Biol 15:e2001644","journal-title":"PLoS Biol"},{"key":"3114_CR79","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00000658-198712000-00001","volume":"206","author":"AE Chang","year":"1987","unstructured":"Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M et al (1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206:685\u2013693","journal-title":"Ann Surg"},{"key":"3114_CR80","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/07357909409024872","volume":"12","author":"CG Leichman","year":"1994","unstructured":"Leichman CG (1994) Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials. Cancer Investig 12:166\u2013175","journal-title":"Cancer Investig"},{"key":"3114_CR81","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","volume":"82","author":"H Mitsuya","year":"1985","unstructured":"Mitsuya H, Weinhold K, Furman P, St Clair MH, Lehrman SN et al (1985) 3\u2032-Azido-3\u2032-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82:7096\u20137100","journal-title":"Proc Natl Acad Sci USA"},{"key":"3114_CR82","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","volume":"83","author":"P Furman","year":"1986","unstructured":"Furman P, Fyfe J, St Clair MH, Weinhold K, Rideout J et al (1986) Phosphorylation of 3\u2032-azido-3\u2032-deoxythymidine and selective interaction of the 5\u2032-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83:8333\u20138337","journal-title":"Proc Natl Acad Sci USA"},{"key":"3114_CR83","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s10096-011-1220-3","volume":"30","author":"A Dol\u00e9ans-Jordheim","year":"2011","unstructured":"Dol\u00e9ans-Jordheim A, Bergeron E, Bereyziat F, Ben-Larbi S, Dumitrescu O et al (2011) Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. Eur J Clin Microbiol Infect Dis 30:1249\u20131256","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3114_CR84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0149-2918(98)80031-3","volume":"20","author":"JW Beach","year":"1998","unstructured":"Beach JW (1998) Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther 20:2\u201325","journal-title":"Clin Ther"},{"key":"3114_CR85","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/AAC.31.2.274","volume":"31","author":"LP Elwell","year":"1987","unstructured":"Elwell LP, Ferone R, Freeman GA, Fyfe JA, Hill JA et al (1987) Antibacterial activity and mechanism of action of 3\u2032-azido-3\u2032-deoxythymidine (BW A509U). Antimicrob Agents Chemother 31:274\u2013280","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR86","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/BF01963765","volume":"8","author":"CS Lewin","year":"1989","unstructured":"Lewin CS, Amyes SG (1989) Conditions required for the antibacterial activity of zidovudine. Eur J Clin Microbiol Infect Dis 8:737\u2013741","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3114_CR87","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0002-9343(88)80340-1","volume":"85","author":"MR Blum","year":"1988","unstructured":"Blum MR, Liao SH, Good SS, de Miranda P (1988) Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 85:189\u2013194","journal-title":"Am J Med"},{"key":"3114_CR88","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/clpt.1987.49","volume":"41","author":"RW Klecker Jr","year":"1987","unstructured":"Klecker RW Jr, Collins JM, Yarchoan R, Thomas R, Jenkins JF et al (1987) Plasma and cerebrospinal fluid pharmacokinetics of 3\u2032-azido-3\u2032-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 41:407\u2013412","journal-title":"Clin Pharmacol Ther"},{"issue":"2A","key":"3114_CR89","first-page":"186","volume":"85","author":"KM Ayers","year":"1988","unstructured":"Ayers KM (1988) Preclinical toxicology of zidovudine. An overview. Am J Med 85(2A):186\u2013188","journal-title":"Am J Med"},{"key":"3114_CR90","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0140-6736(88)90152-3","volume":"332","author":"M Hargreaves","year":"1988","unstructured":"Hargreaves M, Fuller G, Costello C, Gazzard B (1988) Zidovudine overdose. Lancet 332:509","journal-title":"Lancet"},{"key":"3114_CR91","first-page":"1206","volume":"318","author":"OB Pickus","year":"1988","unstructured":"Pickus OB (1988) Overdose of zidovudine. N Engl J Med 318:1206","journal-title":"N Engl J Med"},{"key":"3114_CR92","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/AAC.33.4.479","volume":"33","author":"BR Keith","year":"1989","unstructured":"Keith BR, White G, Wilson HR (1989) In vivo efficacy of zidovudine (3\u2032-azido-3\u2032-deoxythymidine) in experimental gram-negative-bacterial infections. Antimicrob Agents Chemother 33:479\u2013483","journal-title":"Antimicrob Agents Chemother"},{"key":"3114_CR93","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1126\/science.8153626","volume":"264","author":"BG Spratt","year":"1994","unstructured":"Spratt BG (1994) Resistance to antibiotics mediated by target alterations. Science 264:388\u2013393","journal-title":"Science"},{"key":"3114_CR94","first-page":"141","volume":"58","author":"CS Lewin","year":"1990","unstructured":"Lewin CS, Watt B, Paton R, Amyes SGB (1990) Isolation of zidovudine resistant Escherichia coli from AIDS patients. FEMS Microbiol Lett 58:141\u2013143","journal-title":"FEMS Microbiol Lett"},{"key":"3114_CR95","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jac\/25.4.706","volume":"25","author":"CS Lewin","year":"1990","unstructured":"Lewin CS, Allen R, Amyes SGB (1990) Zidovudine-resistance in Salmonella typhimurium and Escherichia coli. J Antimicrob Chemother 25:706\u2013708","journal-title":"J Antimicrob Chemother"},{"key":"3114_CR96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1099\/00222615-33-4-235","volume":"33","author":"CS Lewin","year":"1990","unstructured":"Lewin CS, Allen RA, Amyes SGB (1990) Mechanisms of zidovudine resistance in bacteria. J Med Microbiol 33:235\u2013238","journal-title":"J Med Microbiol"},{"key":"3114_CR97","unstructured":"Hu Y, Coates A (2014) Combination comprising zidovudine and polymyxin. WO 2014147405 A1"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-017-3114-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-017-3114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-017-3114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T04:29:43Z","timestamp":1659587383000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-017-3114-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3114"],"URL":"https:\/\/doi.org\/10.1007\/s10096-017-3114-5","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,10]]}}}